Recent Quotes
My Watchlist
Indicators
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

Biogen, Inc. (NQ: BIIB )

227.03 USD -2.47 (-1.08%)
Streaming Delayed Price Updated: 11:19 AM EST, Dec 2, 2021 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press releases about Biogen, Inc.

< Previous 1 2 3 4 5 6 Next >
Sage Therapeutics and Biogen Announce Positive, One-Year Zuranolone 50 mg Data in the Ongoing Open-Label SHORELINE Study in Patients with MDD
Sage Therapeutics, Inc. (Nasdaq: SAGE), and Biogen Inc. (Nasdaq: BIIB) today announced 12-month data for the cohort of patients (n=199), who received zuranolone 50 mg once nightly for 14-days as their... 
From Business Wire News Releases
From Pause to Pride: A Mother's Journey
Tags Biogen NASDAQ:BIIB Diversity & Inclusion
From 3BL Media: Corporate Social Responsibility, Energy and Health News
Youth Neurology Program: Building a More Diverse Neurology Workforce
Tags Diversity & Inclusion NASDAQ:BIIB Biogen
From 3BL Media: Corporate Social Responsibility, Energy and Health News
Wanda Castro-Borrero: Carrying on Legacy of Care
Tags Diversity & Inclusion NASDAQ:BIIB Biogen
From 3BL Media: Corporate Social Responsibility, Energy and Health News
Global Cancer Therapy Market Expected to Reach $268 Billion In 2026, With A CAGR Of 9.15%
Tags Featured News
From FinancialNewsMedia.com Newswire for Stock Alerts, Public Company News Alert
Biogen Sets Industry Record with Recognition on Dow Jones Sustainability World Index for 9th Consecutive Year
Tags NASDAQ:BIIB Biogen Dow Jones Sustainability Index
From 3BL Media: Corporate Social Responsibility, Energy and Health News
CEO Climate Alliance to World Leaders: We Support You in Taking Decisive Climate Steps at COP26
Tags The Alliance of CEO Climate Leaders Biogen Environment
From 3BL Media: Corporate Social Responsibility, Energy and Health News
Biogen Launches Supplier Climate Action Program “Energize” With Leading Pharmaceutical Companies
Tags climate action Energize Supply Chain & the Circular Economy
From 3BL Media: Corporate Social Responsibility, Energy and Health News
Introducing Biogen's 2021 Diversity, Equity & Inclusion Report
Tags Research, Reports & Publications Biogen Diversity & Inclusion
From 3BL Media: Corporate Social Responsibility, Energy and Health News
A Letter From Alphonse Galdes, Ph.D., Head of Pharmaceutical Operations and Technology at Biogen: It's Time for Companies to Act Like the Climate Crisis Is a Health Crisis
Tags Alphonse Galdes NASDAQ:BIIB Biogen
From 3BL Media: Corporate Social Responsibility, Energy and Health News
MIT Collaborates With Biogen on Three-Year, $7 Million Initiative to Address Climate, Health, and Equity
Tags Responsible Business & Employee Engagement MIT NASDAQ:BIIB
From 3BL Media: Corporate Social Responsibility, Energy and Health News
MSM Students to Participate in Biogen's Summer Health Equity Fellowship Program
Tags NASDAQ:BIIB Biogen Morehouse School of Medicine
From 3BL Media: Corporate Social Responsibility, Energy and Health News
Sage Therapeutics and Biogen Announce Plans to Submit a New Drug Application (NDA) for Zuranolone to the U.S. Food & Drug Administration in the Second Half of 2022 with Rolling Submission Expected to
Sage Therapeutics, Inc. (Nasdaq: SAGE) and Biogen Inc. (Nasdaq: BIIB) today announced their plan to submit a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for zuranolone, an... 
From Business Wire News Releases
Healthy Climate, Healthy Lives: Advancing Strategic Collaborations
Tags Biogen NASDAQ:BIIB Health & Healthcare
From 3BL Media: Corporate Social Responsibility, Energy and Health News
Global Atopic Dermatitis Treatment Market Size Is Projected To Be Worth US$21.80 Billion By 2026
Tags Featured News
From FinancialNewsMedia.com Newswire for Stock Alerts, Public Company News Alert
Healthy Climate, Healthy Lives: Engaging Employees and Suppliers
Tags Environment Sustainability Healthy Climate Healthy Lives
From 3BL Media: Corporate Social Responsibility, Energy and Health News
Sage Therapeutics and Biogen Announce Consistent Clinically Meaningful Data for Zuranolone Across the LANDSCAPE and NEST Clinical Development Programs Presented at the European College of Neuropsychop
Sage Therapeutics, Inc. (Nasdaq: SAGE) and Biogen Inc. (Nasdaq: BIIB) today announced new data from the LANDSCAPE and NEST clinical development programs evaluating the efficacy and safety of zuranolone... 
From Business Wire News Releases
Healthy Climate, Healthy Lives: Fossil Fuel Free Operations
Tags Healthy Climate Healthy Lives Environment Biogen
From 3BL Media: Corporate Social Responsibility, Energy and Health News
Biogen Issues First Progress Report of its Signature Healthy Climate, Healthy Lives™ Initiative
Tags Research, Reports & Publications Biogen NASDAQ:BIIB
From 3BL Media: Corporate Social Responsibility, Energy and Health News
Biogen R&D Day to Provide Overview of Diversified Pipeline and Capabilities with Potential for Multiple Novel Therapies in Neuroscience
From GlobeNewswire News Releases
FDA Approves Samsung Bioepis and Biogen’s BYOOVIZ™ (SB11), LUCENTIS® Biosimilar (ranibizumab-nuna)
From GlobeNewswire News Releases
FDA Approves Samsung Bioepis and Biogen’s BYOOVIZ™ (SB11), LUCENTIS® Biosimilar (ranibizumab-nuna)
From GlobeNewswire News Releases
CHMP Recommends VUMERITY® (diroximel fumarate) for Approval in the European Union as a Treatment for Relapsing-Remitting Multiple Sclerosis
From GlobeNewswire News Releases
Biogen Announces Positive Topline Results from Phase 2 CONVEY Study in Small Fiber Neuropathy
Vixotrigine, a non-opioid investigational pain drug, has the potential to address significant unmet medical needs of individuals living with chronic painful neuropathy 
From GlobeNewswire News Releases
Biogen Plans to Initiate Phase 3b Study Evaluating Potential Benefit of a Higher Dose of Nusinersen in Patients Previously Treated with Evrysdi® (risdiplam)
From GlobeNewswire News Releases
Biogen Announces Results from Phase 3b NOVA Study Evaluating Every Six-Week Dosing with Natalizumab in Relapsing-Remitting Multiple Sclerosis
From GlobeNewswire News Releases
Biogen and Eisai Announce Design of ADUHELM ICARE AD-US Study, the First Real-World Observational Phase 4 Study in Alzheimer's Disease at AAIC 2021
From ACN Newswire
Biogen and Eisai Announce Design of ADUHELM ICARE AD-US Study, the First Real-World Observational Phase 4 Study in Alzheimer’s Disease at AAIC 2021
From GlobeNewswire News Releases
Biogen and Eisai Announce ADUHELMTM (aducanumab-avwa) Data Presentations at Alzheimer's Association International Conference 2021
From ACN Newswire
Biogen and Eisai Announce ADUHELM™ (aducanumab-avwa) Data Presentations at Alzheimer’s Association International Conference 2021
From GlobeNewswire News Releases
< Previous 1 2 3 4 5 6 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.